Low doses of anti-VEGF therapy with ranibizumab are effective in infants with retinopathy of prematurity (ROP), according to results from the CARE-ROP study, as reported in Medscape.
"The CARE-ROP results show that both ranibizumab doses (24% vs. 40% of the adult dose) were equally effective in treating ROP (94% vs. 93% success in per-protocol treated eyes),” Dr. Andreas Stahl from University of Freiburg, in Germany, told Reuters Health by email. “Systemic VEGF levels were not suppressed following ranibizumab treatment.”
Vascular endothelial growth factor (VEGF) is a main driver of ROP pathophysiology. The anti-VEGF bevacizumab halts progression of severe ROP but suppresses VEGF plasma levels for weeks, raising questions about potential adverse effects on organ development in infants.